פטרית הפלא היפאנית מייטקי. האם יעילה בחולי סרטן?

המיתוס - הפטריה: 1) מעלימה גידולים סרטניים ו 2) מחזקת את מערכת החיסון של החולה. http://www.bteva.co.il/ProductPage.asp?PID=2083&CatID= לפי פרסום זה, המחקר היפאני בחולי סרטן מרשים. האומנם? Where is the evidence? http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Maitake_Mushroom.asp?sitearea=ETO מסקנה: ככה לא בונים חומה (= ככה לא עורכים מחקר מדעי). Oncology (Williston Park). 2008 Sep;22(10):1202. | Complementary therapies, herbs, AND other OTC agents. Cassileth B. Memorial Sloan-Kettering Cancer Center, New York, New York, USA. Graviola demonstrated anticancer effects in vitro, but has not been studied in humans. Despite the lack of human data, many websites promote graviola to cancer patients based on traditional use AND on the in vitro studies. Caution is required as there is no evidence of safety OR efficacy. ומה לגבי הטענה שהפטריה מחזקת את מערכת החיסון? J Cancer Res Clin Oncol. 2009 Mar 1. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Deng G, Lin H, Seidman A, Fornier M, D'Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, Vickers AJ, Cassileth B. Integrative Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA, BACKGROUND: Cancer patients commonly use dietary supplements to "boost immune function". A polysaccharide extract from Grifola frondosa (Maitake extract) showed immunomodulatory effects in preclinical studies AND therefore the potential for clinical use. Whether oral administration in human produces measurable immunologic effects, however, is unknown. METHODS: In a phase I/II dose escalation trial, 34 postmenopausal breast cancer patients, free of disease after initial treatment, were enrolled sequentially in five cohorts. Maitake liquid extract was taken orally at 0.1, 0.5, 1.5, 3, OR 5 mg/kg twice daily for 3 weeks. Peripheral blood was collected at days -7, 0 (prior to the first dosing), 7, 14, AND 21 for ex vivo analyses. The primary endpoints were safety AND tolerability. RESULTS: No dose-limiting toxicity was encountered. Two patients withdrew prior to completion of the study due to grade I possibly related side effects: nausea AND joint swelling in one patient; rash AND pruritus in the second. There was a statistically significant association between Maitake AND immunologic function (p < 0.0005). Increasing doses of Maitake increased some immunologic parameters AND depressed others; the dose-response curves for many endpoints were non-monotonic with intermediate doses having either immune enhancing OR immune suppressant effects compared with both high AND low doses. CONCLUSIONS: Oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory AND inhibitory measurable effects in peripheral blood. Cancer patients should be made aware of the fact that botanical agents produce more complex effects than assumed, AND may depress as well as enhance immune function.